CERU Description — Cerulean Pharma Inc
Cerulean Pharma is a clinical-stage, oncology-focused company applying its proprietary Dynamic Tumor Targeting Platform to develop various therapies. Co.'s platform is designed to create nanoparticle-drug conjugates, which consist of anti-cancer therapeutics, or payloads, covalently linked to a proprietary polymer. Co.'s principal clinical candidate, CRLX101, is in Phase 2 clinical development in patients with renal cell carcinoma and in Phase 2 and Phase 1b clinical development in patients with ovarian cancer in combination with Avastin® (bevacizumab) and paclitaxel, respectively. Co.'s second clinical candidate, CRLX301, is in Phase 1/2a clinical development.